ArticleBrain communications2020
Cerebrovascular disease promotes tau pathology in Alzheimer's disease.
Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysis.Alzheimer's research & therapy · 2025Pooled it
- Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Pooled it
- Association between lower body temperature and increased tau pathology in cognitively normal older adults.Neurobiology of disease · 2022Trial
- A collaborative framework for uncovering molecular and cellular drivers of VCID: Foundations for future interventions in dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Discrete White Matter Lesions in Clusters and Harmony: Using Oblique Strategies to Study Brain Aging.Diabetes care · 2026Article
- Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Stage-Dependent mediation of white matter hyperintensities between plasma biomarkers and cognitive function in Alzheimer's disease.Translational psychiatry · 2026Article
- Neuropathological links between plasma p-Tau 181, white matter hyperintensity, and structural brain changes in aging.Quantitative imaging in medicine and surgery · 2026Article
- Neuroprotective mechanism of hydrogen sulfide in okadaic acid-induced alzheimer-like pathology.GeroScience · 2026Article
- Medial temporal lobe atrophy is associated with age and pathologies, especially small vessel disease.Scientific reports · 2026Article
- Trends in Cerebrovascular Disease Mortality Among Alzheimer Patients in Older Adults Across the USA: A CDC Wonder Analysis.Current Alzheimer research · 2026Article
- Synergistic effects of cerebral small vessel disease burden and plasma phosphorylated tau 181 on white matter microstructure and cognition in a Chinese cohort.Brain communications · 2026Article
- Enhancing brain age estimation with structural MRI and synthesized cerebral blood volume maps.Brain communications · 2026Article
- Oxygen extraction fraction is differentially associated with pathological biomarkers in Alzheimer's disease and non-Alzheimer's dementias.Frontiers in neuroscience · 2026Article
- Distinct cerebrovascular pathways underlying Alzheimer's disease-related neurodegeneration.Acta neuropathologica · 2025Article
- Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Arteriosclerosis in the heart-brain axis and Alzheimer's disease plasma markers in the Rotterdam Study.Journal of Alzheimer's disease : JAD · 2025Article
- Impact of regional white matter hyperintensity patterns on cognitive trajectories in NACC.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Synergistic effects of multiple pathological processes on Alzheimer's disease risk: Evidence for age-dependent stroke interactions.The journal of prevention of Alzheimer's disease · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer's disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer's pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer's disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer's Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer's disease (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.